The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients.

Three trials showed no improvement in functional outcomes, and the potential for harm, versus medical therapy alone.

Donald Trump's aides are fully supportive of Elon Musk's efforts to drastically cut government spending, but his decisions ...

For more than a decade, the Food and Drug Administration (FDA) has made diversity in clinical trials a focus, including by issuing guidance, ...

BIO CEO & Investor conference Format: "IPO Class of 2024 Panel" and one-on-one meetings Date: February 10, 2025 Location: New York, NY Registered conference attendees may schedule one-on-one meetings ...

The gender data gap refers to the systemic lack of data relevant to the experiences of women and girls. This is particularly ...

Following the president’s recent executive order dismantling diversity, equity, and inclusion policies, the main page for the ...

Annovis Bio has commenced the treatment of subjects in a Phase III clinical trial of buntanetap in treating early Alzheimer's ...

Kura and Kyowa used the announcement to confirm that they are on track to file a new drug approval application with the FDA ...

Northwestern Medicine is a global leader in clinical trial research, including spineCLARITY is a randomized study designed to demonstrate ...

Cerebral cavernous malformation (CCM) patients treated with oral drug, REC-994, showed reduction in total cerebral and brainstem lesion volume.

An investor who sued Verve Therapeutics Inc. for allegedly misleading investors about a clinical trial for its cholesterol medicine has voluntarily dismissed the proposed class action.